The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.
GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.
Please see enclosed pdf.
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted:
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area.
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based products for the treatment of Diabetic Foot Ulcers (DFUs) and venous leg ulcers (VLUs) in the Medicare population.
The Annual General Meeting of Coloplast A/S will be held on
Thursday, 5 December 2024 at 3:30 pm CET
at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark.
The notice of the Annual General Meeting is enclosed.
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24
Coloplast expands Executive Leadership Team
Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect.
Tuesday, 5 November 2024 at 11.00 – 12.00 CET
In connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.
A presentation will be available on Coloplast's website approximately 1 hour before the conference call.
Please note that the webcast of the conference call will be available during and after the event.
Please see enclosed pdf.
Please see enclosed pdf.
Please see enclosed pdf.
Please see enclosed pdf.
Please see enclosed pdf.
9M 2023/24
Interim financial results, 9M 2023/24
1 October 2023 - 30 June 2024
The event will take place on Thursday, 6 June 2024 at Coloplast’s Headquarters
Holtedam 3, 3050 Humlebaek, Denmark
from 11.30 - 18.00 CEST (Central European Summer Time)
The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2.
The company has received reimbursement approval in the UK for Heylo™, the world’s first digital leakage notification system, and expands its SenSura® Mio ostomy range with two new products.
H1 2023/24
Interim financial results, H1 2023/24
1 October 2023 - 31 March 2024
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.